Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: GlobeNewswire
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ: OCUL). The investigation focuses on Ocular’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Ocular securities? If you purchased Ocular securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471. There is no cost or obligation to you. Background of the investigation On February 17, 2026, Ocular announced topline results from its SOL-1 Phase 3 trial. The company disclosed that 74% of patients maintained vision at nine months, 66% maintained vision at twelve months, and approximately 69% were rescue-free at 52 weeks. Following this disclosure, Ocular’s stock price declined approximately 27%. In light of these di
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.MarketBeat
- Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript [Seeking Alpha]Seeking Alpha
- Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect [Seeking Alpha]Seeking Alpha
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]Yahoo! Finance
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- OCUL's page on the SEC website